Human tumor antigens recognized by T cells and their implications for cancer immunotherapy

Ryo Ueda, Tomonori Yaguchi, Yutaka Kawakami

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.

Original languageEnglish
Title of host publicationInnate Immune Regulation and Cancer Immunotherapy
PublisherSpringer New York
Pages335-345
Number of pages11
ISBN (Print)9781441999146, 9781441999139
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Neoplasm Antigens
Immunotherapy
T-Lymphocytes
Neoplasms
Melanoma
Adoptive Transfer
Whole-Body Irradiation
Cytotoxic T-Lymphocytes
Cyclophosphamide
Clinical Trials
Cytokines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ueda, R., Yaguchi, T., & Kawakami, Y. (2012). Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. In Innate Immune Regulation and Cancer Immunotherapy (pp. 335-345). Springer New York. https://doi.org/10.1007/9781441999146_19

Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. / Ueda, Ryo; Yaguchi, Tomonori; Kawakami, Yutaka.

Innate Immune Regulation and Cancer Immunotherapy. Springer New York, 2012. p. 335-345.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ueda, R, Yaguchi, T & Kawakami, Y 2012, Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. in Innate Immune Regulation and Cancer Immunotherapy. Springer New York, pp. 335-345. https://doi.org/10.1007/9781441999146_19
Ueda R, Yaguchi T, Kawakami Y. Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. In Innate Immune Regulation and Cancer Immunotherapy. Springer New York. 2012. p. 335-345 https://doi.org/10.1007/9781441999146_19
Ueda, Ryo ; Yaguchi, Tomonori ; Kawakami, Yutaka. / Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. Innate Immune Regulation and Cancer Immunotherapy. Springer New York, 2012. pp. 335-345
@inbook{c7d181e95d5940ac927612a9eee5d928,
title = "Human tumor antigens recognized by T cells and their implications for cancer immunotherapy",
abstract = "Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70{\%} of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.",
author = "Ryo Ueda and Tomonori Yaguchi and Yutaka Kawakami",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/9781441999146_19",
language = "English",
isbn = "9781441999146",
pages = "335--345",
booktitle = "Innate Immune Regulation and Cancer Immunotherapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - Human tumor antigens recognized by T cells and their implications for cancer immunotherapy

AU - Ueda, Ryo

AU - Yaguchi, Tomonori

AU - Kawakami, Yutaka

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.

AB - Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.

UR - http://www.scopus.com/inward/record.url?scp=84955389375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955389375&partnerID=8YFLogxK

U2 - 10.1007/9781441999146_19

DO - 10.1007/9781441999146_19

M3 - Chapter

SN - 9781441999146

SN - 9781441999139

SP - 335

EP - 345

BT - Innate Immune Regulation and Cancer Immunotherapy

PB - Springer New York

ER -